Halozyme Therapeutics Inc. (HALO)
BMV
1,968.69
0.00 (0.00%)
Closed
Oct 8, 2026
Day's Range
1,968.691,968.69
52 wk Range
1,121.861,970.00
Financial Statements - HALO - Halozyme Therapeutics Inc.
Revenue
1.39B▼ 92.0%
Net Income
316.88M▼ 95.9%Net Margin 22.7%
EBITDA
890.64M▼ 91.8%
Free Cash Flow
356.81M▼ 95.6%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | 1.39B | 17.48B |
| Cost of Goods | 228.77M | 2.74B |
| Gross Profit | 1.16B | 14.73B |
 Operating Expense | - | - |
| Operating Income | 802.59M | 9.49B |
| Non-Operating Interest | - | - |
| Other Income Expense | -317.59M | 408.94M |
| Pre Tax Income | 466.87M | 9.59B |
| Income Tax | 149.98M | 1.94B |
| Net Income | 316.88M | 7.64B |
| EPS Basic | 2.64 | 3.5 |
| EPS Diluted | 2.56 | 3.43 |
| Basic Shares Outstanding | 119.84M | 2.18B |
| Diluted Shares Outstanding | 119.84M | 2.18B |
| Ebit | 485M | 9.90B |
| Ebitda | 890.64M | 10.89B |
| Net Income Continuous Operations | 316.88M | 7.64B |
| Minority Interests | - | - |
| Preferred Stock Dividends | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
